[go: up one dir, main page]

PE10396A1 - Formulacion farmaceutica administrada oralmente - Google Patents

Formulacion farmaceutica administrada oralmente

Info

Publication number
PE10396A1
PE10396A1 PE1995262772A PE26277295A PE10396A1 PE 10396 A1 PE10396 A1 PE 10396A1 PE 1995262772 A PE1995262772 A PE 1995262772A PE 26277295 A PE26277295 A PE 26277295A PE 10396 A1 PE10396 A1 PE 10396A1
Authority
PE
Peru
Prior art keywords
oil
agent
acid
east
useful
Prior art date
Application number
PE1995262772A
Other languages
English (en)
Inventor
Stephanie Ann Sweetana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE10396A1 publication Critical patent/PE10396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CARACTERIZADA POR COMPRENDER: 1) UN AGENTE FARMACOLOGICO QUE ES SUSTANCIALMENTE INSOLUBLE EN AGUA, TAL COMO UN PEPTIDO CICLICO COMO AUREOBASIDIN A, UTIL COMO FUNGICIDA; Y 2) UN CATALIZADOR SUSTANCIALMENTE NO ACUOSO EN EL CUAL SE DISUELVE DICHO AGENTE, SIENDO EL CATALIZADOR: A) UN AGENTE DISOLVENTE DE ACIDO GRASO DE CADENA LARGA SELECCIONADO A PARTIR DEL GRUPO DE ACIDO OLEICO, ACIDO LINOLEICO Y ACIDO LINOLENICO; B) UN ACEITE FARMACOLOGICAMENTE ACEPTABLE TAL COMO ACEITE DE MAIZ, ACEITE DE OLIVA, ACEITE DE MANI, ACEITE DE SOYA, ACEITE DE GIRASOL Y UNA MEZCLA DE LOS ANTERIORES; Y C) UN AGENTE DE SUPERFICIE ACTIVA SELECCIONADO A PARTIR DEL GRUPO DE POLIGLICERIDOS, ESTERES DE ACIDOS GRASOS SORBITANOS, POLOXAMEROS, ESTERES DE ACIDOS GRASOS SORBITANOS POLIOXIETILENOS, DERIVADOS DE POLIOXIETILENO (POE), ESTERES GRASOS ETOXILATADOS, MONO-GLICERIDOS Y DERIVADOS ETOXILADOS DE LOS MISMOS, DIGLICERIDOS Y DERIVADOS POLIOXIETILENOS DE LOS MISMOS, SULFATO LAURICO DE SODIO, SODIO DOCUSATO, ACIDO COLICO Y SALES DERIVADAS DE LOS MISMOS, LECITINAS Y FOSFOLIPIDOS. ES UTIL PORQUE PERMITE UNA BIODISPONIBILIDAD SUSTANCIAL DEL PRINCIPIO ACTIVO
PE1995262772A 1994-03-01 1995-02-27 Formulacion farmaceutica administrada oralmente PE10396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20342494A 1994-03-01 1994-03-01

Publications (1)

Publication Number Publication Date
PE10396A1 true PE10396A1 (es) 1996-04-11

Family

ID=22753951

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995262772A PE10396A1 (es) 1994-03-01 1995-02-27 Formulacion farmaceutica administrada oralmente

Country Status (15)

Country Link
EP (1) EP0670166A3 (es)
JP (1) JPH0840936A (es)
KR (1) KR950031039A (es)
CN (1) CN1114588A (es)
AU (1) AU1354495A (es)
BR (1) BR9500754A (es)
CA (1) CA2138607A1 (es)
CZ (1) CZ51995A3 (es)
HU (1) HUT75252A (es)
IL (1) IL112745A0 (es)
NO (1) NO950134L (es)
NZ (1) NZ270145A (es)
PE (1) PE10396A1 (es)
PL (1) PL307469A1 (es)
ZA (1) ZA95936B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
EP1058539A1 (en) * 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
JP2012509339A (ja) * 2008-11-20 2012-04-19 テイコク ファーマ ユーエスエー インコーポレーテッド ピラゾロン誘導体製剤
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038073A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
WO2018102345A1 (en) * 2016-11-30 2018-06-07 Agrobiologics Llc Use of the antifungal aureobasidin a in agriculture
US20220160731A1 (en) * 2019-05-20 2022-05-26 Poviva Corp. Compositions comprising biologically active agents and bile salts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
JPH04305534A (ja) * 1991-04-02 1992-10-28 Takara Shuzo Co Ltd オーレオバシジン類製剤
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0672890A (ja) * 1992-06-26 1994-03-15 Nippon Kayaku Co Ltd オーレオバシジン類の乳化製剤

Also Published As

Publication number Publication date
NO950134D0 (no) 1995-01-13
PL307469A1 (en) 1995-09-04
ZA95936B (en) 1995-10-09
CZ51995A3 (en) 1995-10-18
HUT75252A (en) 1997-05-28
EP0670166A3 (en) 1996-06-12
IL112745A0 (en) 1995-05-26
CA2138607A1 (en) 1995-09-02
KR950031039A (ko) 1995-12-18
HU9500618D0 (en) 1995-04-28
JPH0840936A (ja) 1996-02-13
AU1354495A (en) 1995-09-07
BR9500754A (pt) 1995-10-24
NO950134L (no) 1995-09-04
NZ270145A (en) 1996-08-27
CN1114588A (zh) 1996-01-10
EP0670166A2 (en) 1995-09-06

Similar Documents

Publication Publication Date Title
PE10396A1 (es) Formulacion farmaceutica administrada oralmente
ES2276045T3 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de hepatitis c.
ATE215370T1 (de) Selbstemulgierende formulierung enthaltend lipophile verbindungen
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
NO20005431D0 (no) Gelérbare farmasøytiske preparater
ATE497384T1 (de) Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
ES2235899T3 (es) Composicion de micro-emulsion oral de silibin.
US6231887B1 (en) Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
DE60222803D1 (de) Orale kapselformulierung mit verbesserter physikalischer stabilität
DE69211691D1 (de) Pharmazeutische formulierung und pharmazeutisches verfahren
NO20014719L (no) Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
EP0287036A2 (en) New pharmaceutical compositions comprising esters or amides as active ingredients
AU2002334009A1 (en) Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
NO20002590L (no) Formuleringer omfattende oppløst paroxetin
CN100415239C (zh) 非那雄胺高浓度溶液及用途
Gao et al. Case studies: rational development of self-emulsifying formulations for improving the oral bioavailability of poorly soluble, lipophilic drugs
WO2020256349A1 (ko) 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
ES2141049A1 (es) Formulaciones farmaceuticas en aerosol que contienen trigliceridos de cadena media como surfactantes.
TH63649A (th) สารผสมทางเภสัชกรรม
TH18778A (th) สูตรผสมสำหรับสารทางเคมีเภสัชศาสตร์ที่ให้ทางปาก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal